{"id":800571,"date":"2026-05-16T12:47:15","date_gmt":"2026-05-16T12:47:15","guid":{"rendered":"https:\/\/www.europesays.com\/us\/800571\/"},"modified":"2026-05-16T12:47:15","modified_gmt":"2026-05-16T12:47:15","slug":"texas-am-develops-nasal-spray-targeting-brain-fog","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/800571\/","title":{"rendered":"Texas A&M develops nasal spray targeting brain fog"},"content":{"rendered":"

Sinus infections and colds are the typical targets of nasal sprays, but Texas A&M University<\/a> scientists have invented a spray with a more novel aim: getting rid of brain fog.<\/p>\n

Researchers at A&M\u2019s Naresh K. Vashisht College of Medicine<\/a> say their therapy could be revolutionary for patients. By reducing inflammation that causes brain fog and brain aging, it might slow or reverse cognitive decline.\u00a0<\/p>\n

\u201cWe\u2019re creating \u2026 this possibility that we can prevent degenerated cognitive and memory problems,\u201d said\u00a0Ashok Shetty, university distinguished professor and associate director of the Institute for Regenerative Medicine. \u201cYou can potentially prevent Alzheimer’s disease.\u201d<\/p>\n

Shetty and his team are developing the therapy as dementia becomes\u00a0more common in American households, with researchers estimating<\/a> that about 42% of people over 55 are expected to develop it in their lifetimes. New cases of dementia are projected to double, from about 514,000 to 1 million per year by 2060.<\/p>\n

The new nasal spray\u00a0requires more research before it is tested in humans.\u00a0Shetty, who created the therapy along with senior research scientists Madhu Leelavathi Narayana and Maheedhar Kodali, said he expects it will be cheaper, safer and less time-intensive than current therapies, however.<\/p>\n

The treatment is a two-dose spray that is administered over several weeks and lasts for months.<\/p>\n

\u201cThe mode of delivery is one of the most exciting aspects of our approach,\u201d\u00a0Kodali said in a news release. \u201cIntranasal delivery allows us to reach, and treat, the brain directly without invasive procedures.\u201d\u00a0<\/p>\n

The nasal spray\u2019s main target is age-related \u201cneuroinflammaging\u201d in the brain\u2019s center, which develops slowly over time and creates a brain fog that also increases the risk of Alzheimer\u2019s disease.\u00a0<\/p>\n

The spray contains millions of microscopic carriers\u00a0called extracellular vesicles, which carry genetic material known as microRNAs directly to the brain tissue \u2014 entirely bypassing the brain\u2019s protective shield.<\/p>\n

The\u00a0microRNAs are then absorbed into the brain\u2019s immune cells, suppressing systems responsible for chronic inflammation in aging brains.<\/p>\n

In their research, published February in the Journal of\u00a0Extracellular Vesicles<\/a>, Shetty and his team found that two doses of the spray dramatically reduced inflammation and reactivated the brain\u2019s mitochondria, known as \u201cpowerhouse\u201d cells.<\/p>\n

That not only got rid of brain fog, but it also improved the brain\u2019s ability to process and store information, the A&M scientists found.\u00a0Both male and female mice showed better cognitive function and memory recall, including improvements in recognizing familiar objects and detecting new objects and changes in their environment.<\/p>\n

Shetty’s team has filed a patent on the nasal spray. Their study was funded by grants\u00a0from the National Institute on Aging.<\/p>\n","protected":false},"excerpt":{"rendered":"Sinus infections and colds are the typical targets of nasal sprays, but Texas A&M University scientists have invented…\n","protected":false},"author":3,"featured_media":800572,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,67,132,68],"class_list":{"0":"post-800571","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116584333117160488","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/800571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=800571"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/800571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/800572"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=800571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=800571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=800571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}